141 related articles for article (PubMed ID: 22562131)
1. Clinicopathological correlations of mTOR and pAkt expression in non-small cell lung cancer.
Oh MH; Lee HJ; Yoo SB; Xu X; Choi JS; Kim YH; Lee SY; Lee CT; Jheon S; Chung JH
Virchows Arch; 2012 Jun; 460(6):601-9. PubMed ID: 22562131
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of p-Akt, p-mTOR and p-eIF4E proteins associates with metastasis and unfavorable prognosis in non-small cell lung cancer.
Lu J; Zang H; Zheng H; Zhan Y; Yang Y; Zhang Y; Liu S; Feng J; Wen Q; Long M; Fan S
PLoS One; 2020; 15(2):e0227768. PubMed ID: 32023262
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer.
Dhillon T; Mauri FA; Bellezza G; Cagini L; Barbareschi M; North BV; Seckl MJ
J Thorac Oncol; 2010 Mar; 5(3):314-9. PubMed ID: 20093977
[TBL] [Abstract][Full Text] [Related]
4. Prolonged survival after neoadjuvant chemotherapy related with specific molecular alterations in the patients with nonsmall-cell lung carcinoma.
Stojsic J; Stankovic T; Stojkovic S; Milinkovic V; Dinic J; Milosevic Z; Milovanovic Z; Tanic N; Bankovic J
Exp Mol Pathol; 2015 Feb; 98(1):27-32. PubMed ID: 25449334
[TBL] [Abstract][Full Text] [Related]
5. Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells.
Zito CR; Jilaveanu LB; Anagnostou V; Rimm D; Bepler G; Maira SM; Hackl W; Camp R; Kluger HM; Chao HH
PLoS One; 2012; 7(2):e31331. PubMed ID: 22355357
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of phosphorylated mTOR/RPS6KB1 in non- small cell lung cancer.
Zhang Y; Ni HJ; Cheng DY
Asian Pac J Cancer Prev; 2013; 14(6):3725-8. PubMed ID: 23886172
[TBL] [Abstract][Full Text] [Related]
7. mTOR and PTEN expression in non-small cell lung cancer: analysis by real-time fluorescence quantitative polymerase chain reaction and immunohistochemistry.
Wang L; Yue W; Zhang L; Zhao X; Wang Y; Xu S
Surg Today; 2012 May; 42(5):419-25. PubMed ID: 22127531
[TBL] [Abstract][Full Text] [Related]
8. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical characterization of the mTOR pathway in stage-I non-small-cell lung carcinoma.
Shin E; Choi CM; Kim HR; Jang SJ; Park YS
Lung Cancer; 2015 Jul; 89(1):13-8. PubMed ID: 25936472
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylated Akt expression is a prognostic marker in early-stage non-small cell lung cancer.
Yip PY; Cooper WA; Kohonen-Corish MR; Lin BP; McCaughan BC; Boyer MJ; Kench JG; Horvath LG
J Clin Pathol; 2014 Apr; 67(4):333-40. PubMed ID: 24265323
[TBL] [Abstract][Full Text] [Related]
11. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy.
Pantuck AJ; Seligson DB; Klatte T; Yu H; Leppert JT; Moore L; O'Toole T; Gibbons J; Belldegrun AS; Figlin RA
Cancer; 2007 Jun; 109(11):2257-67. PubMed ID: 17440983
[TBL] [Abstract][Full Text] [Related]
12. Expression of the mammalian target of rapamycin pathway markers in lung adenocarcinoma and squamous cell carcinoma.
Kim HS; Kim GY; Lim SJ; Kim YW
Pathobiology; 2012; 79(2):84-93. PubMed ID: 22286903
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 7 receptor activates PI3K/Akt/mTOR signaling pathway via downregulation of Beclin-1 in lung cancer.
Jian M; Yunjia Z; Zhiying D; Yanduo J; Guocheng J
Mol Carcinog; 2019 Mar; 58(3):358-365. PubMed ID: 30362635
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of EGFR-PI3K-pAKT-mTOR-pS6 pathway in sinonasal squamous cell carcinomas.
Muñoz-Cordero MG; López F; García-Inclán C; López-Hernández A; Potes-Ares S; Fernández-Vañes L; Llorente JL; Hermsen M
Acta Otorrinolaringol Esp (Engl Ed); 2019; 70(1):16-24. PubMed ID: 29573781
[TBL] [Abstract][Full Text] [Related]
15. A pilot characterization of human lung NSCLC by protein pathway activation mapping.
Zupa A; Improta G; Silvestri A; Pin E; Deng J; Aieta M; Musto P; Nitti D; Mammano E; Liotta L; Belluco C; Wulfkuhle J; Petricoin E
J Thorac Oncol; 2012 Dec; 7(12):1755-1766. PubMed ID: 23154546
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy.
Shi Y; Chen L; Li J; Lv YL; Sun Q; Wang LX; Jiao SC
Tumour Biol; 2011 Apr; 32(2):381-90. PubMed ID: 21086091
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of CD151 overexpression in non-small cell lung cancer.
Kwon MJ; Seo J; Kim YJ; Kwon MJ; Choi JY; Kim TE; Lee DH; Park S; Shin YK; Han J; Choi YL
Lung Cancer; 2013 Jul; 81(1):109-16. PubMed ID: 23570797
[TBL] [Abstract][Full Text] [Related]
19. Phospho-akt expression is associated with a favorable outcome in non-small cell lung cancer.
Shah A; Swain WA; Richardson D; Edwards J; Stewart DJ; Richardson CM; Swinson DE; Patel D; Jones JL; O'Byrne KJ
Clin Cancer Res; 2005 Apr; 11(8):2930-6. PubMed ID: 15837744
[TBL] [Abstract][Full Text] [Related]
20. Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma.
Yanagawa N; Leduc C; Kohler D; Saieg MA; John T; Sykes J; Yoshimoto M; Pintilie M; Squire J; Shepherd FA; Tsao MS
J Thorac Oncol; 2012 Oct; 7(10):1513-21. PubMed ID: 22982652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]